NuScale's nuclear tech is powering up Wall Street's imagination. Is the stock a game changer or a ticking time bomb? NuScale Power (SMR 1.08%) stock has doubled, but the company still hasn't delivered a working reactor. Is this artificial intelligence (AI)-powered energy bet the next big thing -- or just another Wall Street fad? Discover what's fueling the small modular reactor (SMR) craze and whether NuScale is a brilliant breakthrough or a speculative trap. *Stock prices used were the market prices of Jul ...

Joe Koppeis, Founder & Board Director of Admiral Parkway commented, "We are excited to partner with Terra Innovatum's team to bring their innovative energy technology to the world. Once SOLO™ secures regulatory approval, we will be honored to host the FOAK and take the next steps towards wider commercialization." Gus Garcia, Co-CEO and Director of GSR III Acquisition Corp. said, "Today's announcement is an important milestone for the regulatory and commercial advancement of SOLO™. Terra Innovatum's site sel ...

Core Viewpoint - ProKidney Corp. is actively engaging with investors through participation in the H.C. Wainwright 4 Annual Kidney Virtual Conference, highlighting its focus on chronic kidney disease and its innovative cellular therapy approach [1]. Company Overview - ProKidney Corp. is a pioneer in chronic kidney disease treatment through cellular therapy innovations, founded in 2015 after a decade of research [2]. - The company's lead product candidate, rilparencel (REACT), is a first-in-class autologous cellular therapy currently in Phase 2 and Phase 3 studies aimed at preserving kidney function in diabetic patients at high risk of kidney failure [2]. - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential significance in the treatment landscape [2].

ProKidney (PROK 515.00%) shares closed at $3.73, rising 515% today while the S&P 500 fell 0.1% and the Dow Jones Industrial Average dropped 0.4%.The chronic kidney disease-focused biotech experienced significant volatility, trading between $0.46 and $4.86 before settling near its upper range. The gain follows ProKidney's announcement of statistically and clinically meaningful topline results from its Phase 2 REGEN-007 clinical trial evaluating is autologous cell therapy treatment, called rilparencel, in pat ...

As tariff fears ripple across markets with President Donald Trump sending tariff letters to 12 countries, small-cap resilience is stealing the spotlight. The Russell 2000 index is soaring toward creating new all-time highs. The iShares Russell 2000 ETF IWM, which tracks the Russell 2000 index, is up over 25% from April 8 lows.The recovery is powered in part by a few unlikely stars – Oklo Inc OKLO, NuScale Power Corp SMR and Hims & Hers Health Inc HIMS – each bucking macro gloom with year-to-date gains of 15 ...

NANO Nuclear Signs a Memorandum of Understanding with UrAmerica Ltd. to Help Modernize and Develop Argentina's Nuclear Fuel Supply ChainJuly 08, 2025 9:56 AM EDT | Source: NANO Nuclear Energy Inc.New York, New York--(Newsfile Corp. - July 8, 2025) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has signed a Memorandum of Understanding (MOU) ...

Materials testing enables selection of graphite grade and licensing for its Generation IV Integral Molten Salt Reactor (IMSR) nuclear technology, designed to supply high- temperature, clean, firm and flexible thermal and electric energy, with sector-competitive economics and leading time-to-market at fleet scale Testing leverages world-class testing and research capabilities of the NRG PALLAS Petten Research Centre's High Flux Reactor CHARLOTTE, N.C. and PETTEN, The Netherlands, July 08, 2025 (GLOBE NEWSWIR ...

Results verified by leading global fumed silica supplierMONTREAL, July 08, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutions to support heavy industry in their energy transition, emission reduction, commodity security, and waste remediation efforts, announces today that further to its news release dated Jun ...

It is not all sunshine and rainbows for these high-flying stocks. In fact, the company did have a project in the works in Idaho for six nuclear power modules, but it was cancelled because of a lack of demand. The Department of Energy (DOE) has funded NuScale Power with $600 million, but it still cannot make its products work economically compared to competing energy-generation sources. It also had a proposed project in Utah that was cancelled because of cost overruns. Investors can't seem to get enough of n ...

Core Viewpoint - The nuclear energy industry is experiencing a renaissance, with stocks like Oklo showing significant gains, driven by increasing enthusiasm for nuclear energy and various catalysts supporting its growth [1][7]. Group 1: Factors Driving Oklo's Growth - Oklo's stock surged 559.6% due to multiple catalysts, including letters of intent from two data center customers for deploying its Aurora powerhouse small modular reactors, potentially providing up to 750 megawatts in capacity [3]. - A nonbinding agreement with Switch to deploy 12 gigawatts in Aurora powerhouse projects through 2044 further fueled investor interest [4]. - The announcement of OpenAI's Stargate Project in January 2025, aimed at developing data center infrastructure, attracted more investors to Oklo [4]. Group 2: Political and Regulatory Support - Executive orders signed by President Trump in May to reinvigorate the nuclear energy industry have positively impacted Oklo's stock, reflecting a shift in Washington's attitude towards nuclear development [5]. - The U.S. Nuclear Regulatory Commission's agreement to review Oklo's report for regulatory approval of its Aurora powerhouse represents another significant milestone for the company [9]. Group 3: Market Potential and Future Growth - The demand for data center infrastructure is expected to rise dramatically, with global spending projected to increase from $430 billion in 2024 to $1.1 trillion by 2029, benefiting companies like Oklo [8]. - Oklo's subsidiary, Atomic Alchemy, is advancing in radioisotopic production, with a facility planned in Idaho, which is expected to expand its capabilities in this growing market [10]. - The market for radioisotopic production is projected to grow at an 89.7% compound annual growth rate, from approximately $5.68 billion in 2024 to $953 billion in 2032, indicating substantial future opportunities for Oklo [11].